GlassScriptPhysician profile
Luann R Wolf
NPI 1831266014
$4,758.33
in general payments reported to CMS, 2019-2025
36 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $635 · 2023: $694 · 2024: $1,387 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,433.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.02 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $371.48 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Alexion Pharmaceuticals, INC. | $328.76 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $322.40 | 2024-2025 | |
| Sk Life Science, INC. | $263.28 | 2021-2025 | Xcopri |
| Novo Nordisk INC | $256.14 | 2021-2025 | Ozempic, Rybelsus |
| Harmony Biosciences LLC | $166.91 | 2022-2025 | |
| Lilly USA, LLC | $159.93 | 2022-2023 | Mounjaro |
| Bioventus LLC | $155.32 | 2025 | Exogen Ultrasound Bone Healing System, Durolane |
| Amgen INC. | $155.06 | 2023-2024 | Repatha, Otezla |
| Argenx US, INC. | $124.56 | 2025 | Vyvgart |
| Madrigal Pharmaceuticals | $124.04 | 2025 | Rezdiffra |
| Corium, LLC | $123.00 | 2023 | Azstarys |
| Avadel Cns Pharmaceuticals, LLC | $119.70 | 2025 | Lumryz |
| Axsome Therapeutics, INC. | $118.34 | 2025 | Auvelity |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luann Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.